Study of AFP464 +/- Faslodex in ER + Breast Cancer
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
AFP464 is an investigational agent which may be effective in the treatment of cancer. The
purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer
patients.